Literature DB >> 15717991

Clinical applications of hormonal therapy in ovarian cancer.

Gautam G Rao1, David S Miller.   

Abstract

The ovary is an endocrine organ and an end organ. Hormones and their receptors have been associated with ovarian cancer and may be related to its causation. Some data suggest that hormonal therapies may have some effect on ovarian cancer in palliative settings. No hormonal therapy is approved by the US Food and Drug Administration (FDA) for the treatment of any type of ovarian malignancy nor is it listed as an active agent by any of the authoritative compendia. Because of the endocrine associations with ovarian cancer, the minimal side effects, and demonstrated activity of hormonal therapies in other endocrine-associated malignancies, further study is needed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717991     DOI: 10.1007/s11864-005-0017-y

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  42 in total

1.  High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.

Authors:  B I Sikic; S A Scudder; S C Ballon; O M Soriero; J E Christman; L Suey; M N Ehsan; A E Brandt; T L Evans
Journal:  Semin Oncol       Date:  1986-12       Impact factor: 4.929

2.  Epithelial ovarian carcinoma in patients with intersex disorders: the role of pituitary gonadotropins in ovarian tumorigenesis.

Authors:  D S Miller; N N Teng; S C Ballon
Journal:  Gynecol Oncol       Date:  1986-07       Impact factor: 5.482

3.  Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer.

Authors:  S Wilailak; V Linasmita; S Srisupundit
Journal:  Anticancer Drugs       Date:  2001-10       Impact factor: 2.248

4.  Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women.

Authors:  A K Sugimoto; A B Hodsman; J A Nisker
Journal:  Fertil Steril       Date:  1993-10       Impact factor: 7.329

5.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

6.  Phase II trial of anastrozole in women with asymptomatic müllerian cancer.

Authors:  Marcela G del Carmen; Arlan F Fuller; Ursula Matulonis; Nora K Horick; Annekathryn Goodman; Linda R Duska; Richard Penson; Susana Campos; Maria Roche; Michael V Seiden
Journal:  Gynecol Oncol       Date:  2003-12       Impact factor: 5.482

Review 7.  Estrogens and epithelial ovarian cancer.

Authors:  Séverine Cunat; Pascale Hoffmann; Pascal Pujol
Journal:  Gynecol Oncol       Date:  2004-07       Impact factor: 5.482

8.  WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.

Authors:  Benjamin H Lee; Jonathan L Hecht; Jack L Pinkus; Geraldine S Pinkus
Journal:  Am J Clin Pathol       Date:  2002-05       Impact factor: 2.493

9.  Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.

Authors:  A Fishman; A P Kudelka; D Tresukosol; C L Edwards; R S Freedman; A L Kaplan; R E Girtanner; J J Kavanagh
Journal:  J Reprod Med       Date:  1996-06       Impact factor: 0.142

10.  No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.

Authors:  Ligita Paskeviciute; Henrik Roed; Svend Engelholm
Journal:  Gynecol Oncol       Date:  2002-09       Impact factor: 5.482

View more
  1 in total

1.  Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration.

Authors:  Alessandro Grattoni; Haifa Shen; Daniel Fine; Arturas Ziemys; Jaskaran S Gill; Lee Hudson; Sharath Hosali; Randy Goodall; Xuewu Liu; Mauro Ferrari
Journal:  Pharm Res       Date:  2010-07-01       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.